Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-7831 in hospitalized COVID-19
NCT05780281Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2020; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05780281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780281.